TriLink BioTechnologies has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries.

This agreement with Lonza strengthens TriLink’s objective to drive greater access to CleanCap mRNA capping technologies as the demand for mRNA – a promising therapeutic modality – continues to grow.

According to the terms of the agreement, TriLink will supply its patented CleanCap M6, CleanCap AG 3’OMe, CleanCap AG, and CleanCap AU cap analogs for use in Lonza’s global mRNA development and manufacturing services, from pre-clinical through Phase III programs.

CleanCap technology is a one-pot solution with over 95 percent capping efficiency that streamlines mRNA production processes when compared to legacy capping methods.

“CleanCap technology is accelerating programs from discovery to the clinic via improved mRNA function, streamlined manufacturing, and maximized capped material yield,” shared Drew Burch, President of Nucleic Acid Production at TriLink.

“We’re thrilled to offer our innovative capping solutions to Lonza and its customers,” Bursch added.

Since its launch in 2017, TriLink’s CleanCap capping technology has continued to advance the mRNA capping industry and is used in a majority of approved mRNA and saRNA vaccines. In May 2023, TriLink introduced its most robust CleanCap analog to date, CleanCap M6, with studies indicating increased mRNA expression by more than 30 percent versus enzymatic capping methods.